PE20030132A1 - Compuestos de espiropiperidina como ligandos para el receptor orl-1 - Google Patents

Compuestos de espiropiperidina como ligandos para el receptor orl-1

Info

Publication number
PE20030132A1
PE20030132A1 PE2002000550A PE2002000550A PE20030132A1 PE 20030132 A1 PE20030132 A1 PE 20030132A1 PE 2002000550 A PE2002000550 A PE 2002000550A PE 2002000550 A PE2002000550 A PE 2002000550A PE 20030132 A1 PE20030132 A1 PE 20030132A1
Authority
PE
Peru
Prior art keywords
halo
alkyl
ent
receptor
compounds
Prior art date
Application number
PE2002000550A
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroki Koike
Tatsuya Yangishi
Koji Ando
Masaki Sudo
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20030132A1 publication Critical patent/PE20030132A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DE ESPIROPIPERIDINA DONDE R1 ES H, ALQUILO C1-C6 DON HALO, OH, CARBOXI, ENTRE OTROS. DOS GRUPOS R1 TOMADOS CONJUNTAMENTE FORMAN -CH2-, -(CH2)2- ; R2 ES H, HALO, HIDROXI, ALQUILO C1-C6 CON HALO, OH, CARBOXI, ENTRE OTROS; X1 Y X2 SON (CH2)n1 SIENDO n1 DE 1-3, C[ALQUILO (C1-C6)], C-OH, O, NH, ENTRE OTROS; X1 Y X2 JUNTOS FORMAN CH=CH; W1 Y W2 SON CRw1Rw2 SIENDO Rw1 Y Rw2 H, HALO, HIDROXI, ALQUILO C1-C6, ENTRE OTROS; A ES EL GRUPO AA ENTRE OTROS; Ya SE SELECCIONA ENTRE (CH2)n2 SIENDO n2 UN NUMERO ENTRE 0-2, C(=O), NH, ENTRE OTROS; Z ES C(=O), (CH2)n8 SIENDO n8 DE 0-2. SON COMPUESTO PREFERIDOS CLORHIDRATO DE 2,3-DIHIDRO-1'-[3-(2-METOXICARBONILINDOLIN-1-IL)-3-OXOPROPIL]ESPIRO[1H-INDENO-1,4'-PIPERIDINA], CLORHIDRATO DE 2,3-DIHIDRO-1'-[3-(INDOLIN-1-IL)-3-OXOPROPIL]ESPIRO[1H-INDENO-1,4'-PIPERIDINA], ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON LIGANDOS PARA EL RECEPTOR ORL-1 Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS DEL SNC
PE2002000550A 2001-06-26 2002-06-24 Compuestos de espiropiperidina como ligandos para el receptor orl-1 PE20030132A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30107901P 2001-06-26 2001-06-26

Publications (1)

Publication Number Publication Date
PE20030132A1 true PE20030132A1 (es) 2003-02-28

Family

ID=23161844

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000550A PE20030132A1 (es) 2001-06-26 2002-06-24 Compuestos de espiropiperidina como ligandos para el receptor orl-1

Country Status (12)

Country Link
US (3) US20030078278A1 (es)
EP (1) EP1399432A1 (es)
JP (1) JP2005521630A (es)
AP (1) AP2002002562A0 (es)
BR (1) BR0211305A (es)
CA (1) CA2450550A1 (es)
MX (1) MXPA03011956A (es)
PA (1) PA8549101A1 (es)
PE (1) PE20030132A1 (es)
SV (1) SV2003001115A (es)
UY (1) UY27355A1 (es)
WO (1) WO2003000677A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307268A (pt) * 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
CN100402529C (zh) * 2002-09-09 2008-07-16 詹森药业有限公司 用于治疗orl-1受体介导疾病的羟基烷基取代的1,3,8-三氮杂螺[4,5]癸-4-酮衍生物
US7247725B2 (en) * 2002-10-30 2007-07-24 Merck & Co., Inc. Gamma-aminoamide modulators of chemokine receptor activity
MXPA05010724A (es) 2003-04-04 2005-12-15 Merck & Co Inc Derivados de las espiropiperidinas aciladas como agonistas del receptor de la melanocortina-4.
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
EP1732893A2 (en) * 2004-03-29 2006-12-20 Pfizer Japan, Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
WO2005117862A1 (en) * 2004-06-03 2005-12-15 Pfizer Limited, Treatment of urinary conditions including incontinence
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
EP1890696A4 (en) * 2005-06-02 2010-05-05 Janssen Pharmaceutica Nv Suitable as new ORL-1 receptor modulators are 3-pyrolytic indolyl derivatives
EP1893610A2 (en) * 2005-06-17 2008-03-05 Pfizer, Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
MX2007016215A (es) * 2005-06-17 2008-03-07 Pfizer Compuestos del acido alfa-(aril-o heteroaril-metil)-beta-piperidin opropanoico como antagonistas del receptor orl1.
WO2007047496A2 (en) 2005-10-18 2007-04-26 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
US20080015214A1 (en) * 2005-10-24 2008-01-17 Bignan Gilles C 3-piperidin-4-yl-indole orl-1 receptor modulators
WO2007057775A1 (en) * 2005-11-21 2007-05-24 Pfizer Limited Spiropiperidine derivatives
GB0608452D0 (en) * 2006-04-27 2006-06-07 Glaxo Group Ltd Novel compounds
TW200833695A (en) 2006-10-12 2008-08-16 Xenon Pharmaceuticals Inc Use of spiro-oxindole compounds as therapeutic agents
WO2008056687A1 (fr) * 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
WO2008067167A1 (en) * 2006-11-28 2008-06-05 Janssen Pharmaceutica N.V. Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
WO2008124209A1 (en) * 2007-04-09 2008-10-16 Janssen Pharmaceutica, N.V. 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
NZ600238A (en) 2008-06-19 2014-04-30 Takeda Pharmaceutical Heterocyclic compound and use thereof
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
RU2011119626A (ru) 2008-10-17 2012-11-27 Ксенон Фармасьютикалз Инк. Спирооксиндольные соединения и их применение в качестве терапевтичеких средств
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
EP2488531B1 (en) 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2014146111A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN112940075B (zh) * 2021-01-07 2023-03-31 渤海大学 一种乙酰胆碱酯酶抑制肽及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654287A (en) * 1970-08-26 1972-04-04 Mead Johnson & Co Spiroindanylpiperidines
US3962259A (en) * 1973-12-12 1976-06-08 American Hoechst Corporation 1,3-Dihydrospiro[isobenzofuran]s and derivatives thereof
GB1435054A (en) * 1974-02-04 1976-05-12 Ici Ltd Dihydroanthracene derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
WO1995028389A1 (fr) * 1994-04-15 1995-10-26 Yamanouchi Pharmaceutical Co., Ltd. Compose spiro et composition medicinale issue de ce compose
US5962462A (en) * 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
KR20010020172A (ko) * 1997-05-30 2001-03-15 나가사까 겐지로 2-옥소이미다졸 유도체
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
AU2001288110A1 (en) * 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds

Also Published As

Publication number Publication date
SV2003001115A (es) 2003-03-18
JP2005521630A (ja) 2005-07-21
UY27355A1 (es) 2003-02-28
PA8549101A1 (es) 2003-01-24
EP1399432A1 (en) 2004-03-24
CA2450550A1 (en) 2003-01-03
US20050038060A1 (en) 2005-02-17
US20030078278A1 (en) 2003-04-24
MXPA03011956A (es) 2004-03-26
US20030078279A1 (en) 2003-04-24
AP2002002562A0 (en) 2002-06-30
WO2003000677A1 (en) 2003-01-03
BR0211305A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
PE20030132A1 (es) Compuestos de espiropiperidina como ligandos para el receptor orl-1
DK2774926T3 (en) morphinan
PE20030848A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
ES2834333T3 (es) Inhibidores pirimidinil de tirosina quinasa
AR049701A1 (es) Aminas terciarias no imidazolicas que actuan como inhibidores del receptor de histamina 3 para el tratamiento de trastornos cognitivos y del sueno, obesidad y otros trastornos del snc
CA2479103A1 (en) 1-azabicyclic n-biarylamides with affinity for the alpha7 nicotinic acetylcholine receptor
AR059898A1 (es) Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
PE20041059A1 (es) Quinazolinas como moduladores de canales ionicos
PE20001467A1 (es) Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina
RO117851B1 (ro) Compusi spiranici si compozitie farmaceutica care ii contine
AR068510A1 (es) Derivados de 4-fenil-1h-piridin-2-ona - 1,3 disustituidos, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir trastornos del sistema nervioso central.
ES2076147T3 (es) Nuevos derivados de amina ciclicos, medicamento que contiene estos compuestos y procedimiento para su preparacion.
ES2423668T3 (es) Moduladores de receptores 5-HT y métodos de uso de los mismos
WO1994029309A1 (en) Spiro-substituted azacycles as neurokinin antagonists
AR046309A1 (es) Derivados de dihidrobenzofuranilo alcanamina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos del sistema nervioso central.
JP2017505343A (ja) ホスホイノシチド３−キナーゼ阻害剤としての三環式複素環式化合物
AR055667A1 (es) Compuestos de (piran-piperidinil)becimidazol, composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de trastornos mediados por el agonismo del receptor m1, procesos para prepararlo y compuestos de utilidad como intermediarios de la sintesis de los mismos.
US9505739B2 (en) Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR20090038034A (ko) 5ｈｔ3 조절제로서의 2-아미노벤족사졸 카르복스아미드
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
US20200352931A1 (en) Oxalamides as modulators of indoleamine 2,3-dioxygenase
ES2523541T3 (es) Derivados espirocíclicos como inhibidores de histona desacetilasa
AU2013381199A1 (en) Morphinan derivative
ES2740224T3 (es) 6H-isocromeno[3,4-c]piridinas y benzo[c][1,7]naftiridin-6-(5H)-onas como inhibidores de la cinasa asociada a adaptador 1 (AAK1)
ES2038766T3 (es) 4-aril-5-carbamoil-1,4-dihidropiridinas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal